BIOA bioagelabs.com Earnings growth forecast for next year

BioAge Labs, Inc. (BIOA) researches aging mechanisms to develop highly scalable drugs with low production costs. Shifting analyst expectations for n+1 EPS growth visualize market sentiment, where 2.90 expresses the latest metric level. Molecule synthesis production is outsourced to third-party US bio-factories to ensure research stability. The company's strategy is based on synergy with industry leaders to expand its portfolio of anti-obesity drugs.

BioAge Labs Inc. (BIOA): Expected net earnings per share growth next year from 09/27/2024 to 11/15/2026

BIOA (BioAge Labs): analytical breakdowns and indicator data

- share price and consensus valuation forecast:

Stock Price BioAge Labs, Inc|BIOA - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization BioAge Labs|BIOA - Total Company Value

- book capitalization indicators:

Net Assets per Single Share BioAge Labs, Inc.|BIOA - Total Stockholders' Equity|Market Value to Book Value Ratio bioagelabs.com|BIOA - Aggregate Company Assets

- debt and solvency information:

- net income and valuation ratios data:

BIOA - Net Financial Result|Expected Profit BioAge Labs, Inc.|BIOA - Market Cap to Earnings|Forward P/E Multiple bioagelabs.com|BIOA - PEG Multiple|EV/EBITDA Multiple BioAge Labs|BIOA - Operating profit before depreciation charges|Net earnings per share (EPS TTM) BioAge Labs, Inc.|BIOA - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months bioagelabs.com|BIOA - Earnings per share increase in current year|Net earnings per share growth forecast for next year BioAge Labs, Inc.

- total revenue and sales volume data:

BIOA - Company Revenue|Projected Sales Volume BioAge Labs, Inc|BIOA - P/S Multiple|Forward P/S Multiple BioAge Labs

Initial company analysis:BIOA, bioagelabs.com

This metric serves as a baseline filter for assessing future return on equity. It measures the average expert expectation for the year-over-year change in earnings per share. By analyzing the growth benchmark for earnings per share for the coming year, an investor identifies the gap between market expectations and reality. For BioAge Labs, Inc. (BIOA), this forecast depends critically on regulatory risks and the stability of global raw material supply chains.

Analysis of competing companies